data_5j6t_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5j6t _Structure_validation_residue.Date_analyzed 2017-04-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.217 -0.633 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.7 pt -116.8 27.48 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.389 -0.819 . . . . 0.0 110.262 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.2 t80 -55.91 -42.64 76.36 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.28 -0.888 . . . . 0.0 110.353 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.481 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -61.59 -18.8 57.04 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.02 -15.82 27.33 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.296 -1.12 . . . . 0.0 110.541 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 48.0 mm -84.99 -32.79 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.244 -0.91 . . . . 0.0 110.315 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.461 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -65.24 -51.54 53.12 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 121.357 -0.839 . . . . 0.0 110.194 -179.917 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.481 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 38.0 Cg_exo -54.61 -28.19 54.63 Favored 'Trans proline' 0 C--N 1.314 -1.285 0 O-C-N 123.485 1.255 . . . . 0.0 110.13 179.491 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 12.0 tp -82.71 -27.76 30.99 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.392 -0.817 . . . . 0.0 110.079 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -63.08 -33.37 75.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.42 -0.8 . . . . 0.0 110.02 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.404 ' HA ' HD22 ' A' ' 11' ' ' LEU . 12.8 mt -74.19 -28.57 61.34 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.522 -0.736 . . . . 0.0 110.117 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -76.25 -31.71 54.13 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -59.19 -29.0 67.15 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.419 -1.047 . . . . 0.0 109.964 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 31.3 tp -78.6 -50.11 12.09 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.474 -0.766 . . . . 0.0 110.014 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.0 -27.3 63.38 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.331 -0.856 . . . . 0.0 110.172 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -73.09 -36.6 66.83 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.376 -0.827 . . . . 0.0 110.038 179.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 13.8 tp -72.15 -37.7 69.35 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.389 -0.819 . . . . 0.0 110.021 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 1.3 pp -88.56 -22.02 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.49 -0.756 . . . . 0.0 110.382 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -167.41 82.87 0.21 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.269 -0.894 . . . . 0.0 110.24 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.346 0 O-C-N 119.902 -1.749 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.696 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 5.7 pt -136.93 26.46 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.298 -0.876 . . . . 0.0 110.423 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -62.54 -37.85 87.71 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.42 -0.8 . . . . 0.0 110.087 179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.491 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -60.73 -19.71 55.55 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.772 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.43 -18.27 27.13 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.28 -1.129 . . . . 0.0 110.294 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 49.4 mm -83.15 -33.55 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.229 -0.92 . . . . 0.0 110.397 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.447 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -62.27 -51.89 70.62 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.372 -0.83 . . . . 0.0 110.238 -179.84 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.491 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 31.8 Cg_exo -52.12 -31.43 45.03 Favored 'Trans proline' 0 C--N 1.315 -1.197 0 O-C-N 123.426 1.224 . . . . 0.0 110.222 179.487 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 18.3 mt -77.77 -25.88 49.38 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.444 -0.785 . . . . 0.0 110.029 179.623 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -68.93 -29.17 67.37 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.346 -0.846 . . . . 0.0 110.226 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 6.8 mt -77.39 -24.35 50.55 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.428 -0.795 . . . . 0.0 110.267 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -79.83 -33.78 32.74 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.649 -1.381 . . . . 0.0 109.649 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.23 -32.13 71.92 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.316 -1.108 . . . . 0.0 109.971 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 28.4 tp -78.39 -50.43 11.74 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.486 -0.759 . . . . 0.0 109.867 179.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.4 ' HA ' HG12 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -56.34 -27.97 57.53 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.552 -0.718 . . . . 0.0 110.391 179.947 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 -77.96 -29.23 49.71 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.419 -0.801 . . . . 0.0 110.007 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 tt -76.79 -27.51 55.27 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.367 -0.833 . . . . 0.0 110.276 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.4 HG12 ' HA ' ' A' ' 15' ' ' LYS . 13.6 pt -91.37 -21.93 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.24 -0.912 . . . . 0.0 110.43 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.5 tmtm? -110.46 97.17 6.68 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.353 -0.842 . . . . 0.0 110.259 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.362 0 O-C-N 119.858 -1.776 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.707 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.408 HG23 ' HB3' ' A' ' 5' ' ' ALA . 75.9 mt -106.26 25.3 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.371 -0.831 . . . . 0.0 110.207 . . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.471 ' HA ' HD12 ' A' ' 6' ' ' ILE . 48.1 t80 -67.14 -37.59 84.07 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.26 -0.9 . . . . 0.0 110.156 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.487 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -61.96 -18.18 56.64 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.408 ' HB3' HG23 ' A' ' 2' ' ' ILE . . . -91.72 -20.23 21.78 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.269 -1.136 . . . . 0.0 110.44 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.471 HD12 ' HA ' ' A' ' 3' ' ' PHE . 76.0 mt -83.94 -28.14 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.226 -0.921 . . . . 0.0 110.452 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.483 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -67.74 -52.02 27.62 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.221 -0.925 . . . . 0.0 110.134 179.958 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.487 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 38.2 Cg_exo -54.69 -26.77 48.39 Favored 'Trans proline' 0 C--N 1.312 -1.371 0 O-C-N 123.515 1.271 . . . . 0.0 110.172 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.2 tt -77.74 -28.13 50.68 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.439 -0.788 . . . . 0.0 110.003 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -67.69 -43.64 79.63 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.434 -0.791 . . . . 0.0 110.176 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 5.2 mt -72.39 -29.06 63.4 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.591 -0.693 . . . . 0.0 110.237 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.7 -33.77 76.67 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.497 ' O ' HD22 ' A' ' 17' ' ' LEU . . . -61.74 -29.33 70.04 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.314 -1.109 . . . . 0.0 110.125 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 49.1 tp -81.47 -48.59 11.67 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.369 -0.832 . . . . 0.0 110.072 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.445 ' HA ' ' CG1' ' A' ' 18' ' ' ILE . 0.0 OUTLIER -60.63 -22.63 64.02 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.401 -0.812 . . . . 0.0 110.454 179.978 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -75.31 -37.18 60.92 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.3 -0.875 . . . . 0.0 110.422 -179.739 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.497 HD22 ' O ' ' A' ' 13' ' ' ALA . 4.3 mm? -74.64 -32.65 62.34 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.307 -0.87 . . . . 0.0 110.296 -179.7 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.445 ' CG1' ' HA ' ' A' ' 15' ' ' LYS . 1.3 pp -89.07 -21.73 6.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.406 -0.809 . . . . 0.0 110.416 -179.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 8.4 tttt -121.51 -160.75 0.87 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.308 -0.87 . . . . 0.0 110.15 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.31 0 O-C-N 119.767 -1.833 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.67 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.6 pt -104.84 29.86 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.367 -0.833 . . . . 0.0 110.246 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -74.8 -37.18 62.43 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.451 -0.781 . . . . 0.0 110.188 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.481 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -64.94 -15.96 61.09 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.73 -21.67 20.6 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.241 -1.152 . . . . 0.0 110.368 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 91.3 mt -83.02 -30.11 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.242 -0.911 . . . . 0.0 110.473 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.467 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -65.37 -52.79 43.44 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.362 -0.836 . . . . 0.0 110.11 179.927 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.481 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 31.2 Cg_exo -52.26 -29.09 36.7 Favored 'Trans proline' 0 C--N 1.314 -1.259 0 O-C-N 123.463 1.244 . . . . 0.0 110.276 179.45 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.416 HD11 ' HA ' ' A' ' 9' ' ' LEU . 10.7 tp -77.37 -27.61 52.63 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.438 -0.789 . . . . 0.0 110.032 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -74.09 -32.43 63.24 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.325 -0.859 . . . . 0.0 109.997 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 1.3 mt -78.65 -27.69 45.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.503 -0.748 . . . . 0.0 110.149 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -78.06 -32.98 42.3 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.06 -28.41 69.04 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.36 -1.082 . . . . 0.0 110.095 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 51.5 tp -78.63 -50.65 11.12 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.441 -0.787 . . . . 0.0 110.064 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -57.09 -33.3 67.16 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.307 -0.871 . . . . 0.0 110.18 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -68.84 -37.25 79.02 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.445 -0.784 . . . . 0.0 110.138 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 2.6 tp -67.78 -34.11 76.16 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.281 -0.887 . . . . 0.0 110.193 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.409 HG13 ' N ' ' A' ' 19' ' ' LYS . 22.3 pt -91.21 -23.32 5.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.463 -0.773 . . . . 0.0 110.543 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.409 ' N ' HG13 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -112.2 -60.6 1.84 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.219 -0.925 . . . . 0.0 110.229 179.971 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.363 0 O-C-N 119.871 -1.768 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.669 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.407 HG23 ' HB2' ' A' ' 5' ' ' ALA . 79.1 mt -96.78 16.93 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.312 -0.868 . . . . 0.0 110.369 . . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.3 t80 -61.72 -39.36 91.27 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.209 -0.932 . . . . 0.0 110.11 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.471 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -60.36 -19.46 53.0 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.747 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.407 ' HB2' HG23 ' A' ' 2' ' ' ILE . . . -90.88 -13.6 33.35 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.391 -1.064 . . . . 0.0 110.508 179.846 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 49.1 mm -84.98 -38.91 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.269 -0.894 . . . . 0.0 110.242 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.46 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -60.59 -51.0 82.88 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.368 -0.832 . . . . 0.0 110.516 -179.777 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.471 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 35.7 Cg_exo -55.42 -28.73 65.11 Favored 'Trans proline' 0 C--N 1.314 -1.252 0 O-C-N 123.375 1.197 . . . . 0.0 110.323 179.631 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -79.61 -25.21 41.52 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.477 -0.764 . . . . 0.0 110.255 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -62.32 -33.74 75.27 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.31 -0.869 . . . . 0.0 110.141 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 1.2 mt -75.54 -27.37 58.63 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.411 -0.806 . . . . 0.0 110.206 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -79.04 -31.29 43.58 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.542 ' O ' HD22 ' A' ' 17' ' ' LEU . . . -61.14 -26.92 68.02 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.365 -1.079 . . . . 0.0 109.965 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 29.3 tp -81.05 -50.55 9.52 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.376 -0.827 . . . . 0.0 109.994 179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.413 ' HA ' ' CG1' ' A' ' 18' ' ' ILE . 0.0 OUTLIER -58.35 -26.29 62.96 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.487 -0.758 . . . . 0.0 110.434 -179.829 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.5 m-20 -72.18 -36.72 69.34 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.38 -0.825 . . . . 0.0 110.487 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.542 HD22 ' O ' ' A' ' 13' ' ' ALA . 4.2 mm? -72.98 -36.46 67.09 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.301 -0.874 . . . . 0.0 110.395 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.413 ' CG1' ' HA ' ' A' ' 15' ' ' LYS . 3.7 pt -85.33 -10.4 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.474 -0.766 . . . . 0.0 110.564 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.8 tptt -60.48 147.27 41.78 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.182 -0.949 . . . . 0.0 110.281 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.382 0 O-C-N 119.884 -1.76 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.69 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 4.5 pt -118.86 29.79 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.383 -0.823 . . . . 0.0 110.343 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 33.1 t80 -61.34 -38.83 88.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.384 -0.823 . . . . 0.0 110.187 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.481 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -62.28 -17.81 56.88 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.614 -1.395 . . . . 0.0 109.614 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.11 -15.79 27.24 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.323 -1.104 . . . . 0.0 110.482 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.448 ' HA ' HD13 ' A' ' 6' ' ' ILE . 48.3 mm -85.4 -33.89 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.28 -0.888 . . . . 0.0 110.32 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.477 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -64.45 -51.81 57.54 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.315 -0.865 . . . . 0.0 110.218 -179.847 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.481 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 38.8 Cg_exo -54.88 -28.46 58.68 Favored 'Trans proline' 0 C--N 1.314 -1.254 0 O-C-N 123.357 1.188 . . . . 0.0 110.196 179.483 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -80.25 -27.32 38.69 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.461 -0.774 . . . . 0.0 110.005 179.672 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -73.04 -28.41 62.31 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.386 -0.821 . . . . 0.0 110.062 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.6 mt -78.85 -27.43 44.17 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.418 -0.801 . . . . 0.0 110.199 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -79.3 -35.34 30.1 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.514 ' O ' HD23 ' A' ' 17' ' ' LEU . . . -60.03 -27.46 66.93 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.338 -1.095 . . . . 0.0 110.091 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 58.0 tp -81.88 -48.22 11.8 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.406 -0.809 . . . . 0.0 109.983 179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.411 ' HA ' ' CG1' ' A' ' 18' ' ' ILE . 0.0 OUTLIER -58.34 -27.86 64.55 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.422 -0.799 . . . . 0.0 110.223 179.985 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 90.7 m-20 -70.29 -35.48 73.74 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.349 -0.844 . . . . 0.0 110.459 -179.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.514 HD23 ' O ' ' A' ' 13' ' ' ALA . 4.3 mm? -74.71 -36.76 62.71 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.278 -0.889 . . . . 0.0 110.287 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.411 ' CG1' ' HA ' ' A' ' 15' ' ' LYS . 2.4 pt -89.86 -18.62 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.498 -0.752 . . . . 0.0 110.517 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.404 ' N ' HG13 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -146.49 44.74 1.21 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.226 -0.922 . . . . 0.0 110.261 -179.931 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.354 0 O-C-N 119.927 -1.733 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.696 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.468 HG23 ' HB2' ' A' ' 5' ' ' ALA . 73.8 mt 53.13 25.08 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.305 -0.872 . . . . 0.0 110.516 . . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.531 ' HA ' HD13 ' A' ' 6' ' ' ILE . 50.7 t80 -65.64 -38.65 89.98 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.261 -0.9 . . . . 0.0 110.12 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.488 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -60.95 -19.13 56.01 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.468 ' HB2' HG23 ' A' ' 2' ' ' ILE . . . -90.01 -22.06 22.07 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.256 -1.144 . . . . 0.0 110.36 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.531 HD13 ' HA ' ' A' ' 3' ' ' PHE . 72.7 mt -83.89 -28.6 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.293 -0.88 . . . . 0.0 110.419 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.471 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -64.72 -52.72 49.13 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 121.248 -0.908 . . . . 0.0 110.203 -179.862 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.488 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 33.3 Cg_exo -52.85 -32.03 54.68 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.561 1.295 . . . . 0.0 110.076 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -78.63 -27.36 45.38 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.445 -0.784 . . . . 0.0 109.909 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.41 -43.3 91.01 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.413 -0.804 . . . . 0.0 110.075 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 6.7 mt -67.54 -26.27 66.23 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.432 -0.792 . . . . 0.0 110.157 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -72.12 -34.36 61.52 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.381 -1.487 . . . . 0.0 109.381 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -58.41 -28.12 64.93 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.436 -1.038 . . . . 0.0 110.307 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 62.3 tp -79.0 -46.55 17.96 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.359 -0.838 . . . . 0.0 109.96 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.409 ' HE2' ' CD1' ' A' ' 18' ' ' ILE . 4.9 mmpt? -61.36 -30.71 70.7 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.443 -0.786 . . . . 0.0 109.922 -179.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 68.2 m-20 -76.03 -30.49 58.47 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.4 -0.812 . . . . 0.0 109.832 179.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 tt -71.8 -30.34 65.41 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.417 -0.802 . . . . 0.0 110.118 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.409 ' CD1' ' HE2' ' A' ' 15' ' ' LYS . 12.7 pt -84.3 -21.69 8.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.445 -0.784 . . . . 0.0 110.434 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.406 ' N ' HG13 ' A' ' 18' ' ' ILE . 2.0 tmtt? -104.04 139.26 39.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.245 -0.909 . . . . 0.0 110.166 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.383 0 O-C-N 119.812 -1.805 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.709 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.1 mp -118.22 14.39 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.337 -0.852 . . . . 0.0 110.472 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.439 ' HA ' HD12 ' A' ' 6' ' ' ILE . 58.4 t80 -63.58 -33.12 74.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.136 -0.978 . . . . 0.0 109.879 179.745 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.49 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -63.47 -16.46 58.52 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.616 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.82 -22.12 22.25 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.232 -1.158 . . . . 0.0 110.281 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.439 HD12 ' HA ' ' A' ' 3' ' ' PHE . 79.3 mt -83.16 -30.28 8.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.222 -0.923 . . . . 0.0 110.407 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.465 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -63.44 -52.52 59.67 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.281 -0.887 . . . . 0.0 110.36 -179.908 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.49 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 32.8 Cg_exo -52.81 -31.4 51.45 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 O-C-N 123.347 1.183 . . . . 0.0 110.339 179.614 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.504 ' O ' HD22 ' A' ' 9' ' ' LEU . 2.0 tt -76.96 -27.18 54.7 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.425 -0.797 . . . . 0.0 109.92 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.54 -41.54 92.93 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.428 -0.795 . . . . 0.0 109.969 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 33.2 mt -75.03 -28.91 60.64 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.545 -0.722 . . . . 0.0 110.051 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.54 -32.03 74.47 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -66.34 -26.05 67.1 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.296 -1.12 . . . . 0.0 110.001 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.472 ' O ' HG23 ' A' ' 18' ' ' ILE . 63.2 tp -80.37 -45.93 16.92 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.411 -0.806 . . . . 0.0 110.276 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.44 ' HA ' ' CE ' ' A' ' 15' ' ' LYS . 3.8 mmpt? -68.55 -26.53 65.46 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.345 -0.847 . . . . 0.0 110.002 -179.662 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 3.3 m-20 -81.38 -26.64 35.33 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.295 -0.878 . . . . 0.0 109.656 179.661 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 8.3 tt -77.23 -27.2 53.26 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.476 -0.765 . . . . 0.0 110.243 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.472 HG23 ' O ' ' A' ' 14' ' ' LEU . 14.2 pt -79.76 -21.9 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.322 -0.861 . . . . 0.0 110.331 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.402 ' N ' HG13 ' A' ' 18' ' ' ILE . 2.6 mttt -169.95 72.61 0.07 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.243 -0.911 . . . . 0.0 110.245 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.34 0 O-C-N 119.855 -1.778 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.688 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 47.9 mt -112.15 20.59 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.317 -0.865 . . . . 0.0 110.097 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . 0.401 ' HA ' HD12 ' A' ' 6' ' ' ILE . 46.7 t80 -64.85 -36.41 84.26 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.238 -0.914 . . . . 0.0 109.995 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.487 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -61.98 -18.11 56.55 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 179.857 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -90.16 -21.36 22.25 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.307 -1.114 . . . . 0.0 110.278 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.401 HD12 ' HA ' ' A' ' 3' ' ' PHE . 82.0 mt -83.34 -29.6 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.31 -0.868 . . . . 0.0 110.437 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.47 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -64.39 -52.37 53.98 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.204 -0.935 . . . . 0.0 110.293 -179.916 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.487 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 31.7 Cg_exo -52.48 -31.84 50.27 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 O-C-N 123.485 1.255 . . . . 0.0 110.093 179.556 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.427 HD21 ' O ' ' A' ' 9' ' ' LEU . 0.9 OUTLIER -78.92 -23.73 44.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.425 -0.797 . . . . 0.0 110.044 179.679 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -71.15 -29.67 65.5 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.316 -0.865 . . . . 0.0 110.225 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.424 HD21 ' HA ' ' A' ' 11' ' ' LEU . 79.1 mt -82.09 -27.79 32.68 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.322 -0.861 . . . . 0.0 110.274 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -77.97 -34.57 37.65 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.535 ' O ' HD22 ' A' ' 17' ' ' LEU . . . -64.17 -25.55 68.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.408 -1.054 . . . . 0.0 110.134 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 62.9 tp -85.33 -46.54 10.88 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.345 -0.847 . . . . 0.0 110.035 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.426 ' HA ' ' CE ' ' A' ' 15' ' ' LYS . 4.2 mmpt? -64.31 -21.39 66.59 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.526 -0.734 . . . . 0.0 110.051 -179.813 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -76.58 -36.92 57.27 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.322 -0.861 . . . . 0.0 110.185 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.535 HD22 ' O ' ' A' ' 13' ' ' ALA . 4.2 mm? -73.43 -34.4 65.42 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.356 -0.84 . . . . 0.0 110.124 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.446 HD13 ' HB2' ' A' ' 19' ' ' LYS . 1.7 pp -90.93 -22.43 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.514 -0.741 . . . . 0.0 110.399 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.446 ' HB2' HD13 ' A' ' 18' ' ' ILE . 1.1 tmtt? -137.62 97.63 3.49 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.208 -0.933 . . . . 0.0 110.152 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.282 0 O-C-N 119.798 -1.814 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.214 -0.769 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.8 pt -121.62 24.9 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.336 -0.853 . . . . 0.0 110.271 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -69.64 -45.33 68.72 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.242 -0.911 . . . . 0.0 109.872 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.482 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -67.83 -9.05 55.4 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 179.264 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.23 -27.69 18.29 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.294 -1.121 . . . . 0.0 110.232 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . 0.498 HD13 ' HA ' ' A' ' 6' ' ' ILE . 46.5 mm -82.62 -31.39 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.263 -0.898 . . . . 0.0 110.408 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' TRP . . . . . 0.46 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -61.33 -52.46 70.53 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 121.303 -0.873 . . . . 0.0 110.612 -179.699 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.482 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 31.3 Cg_exo -52.39 -33.59 57.18 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 O-C-N 123.352 1.185 . . . . 0.0 110.288 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.0 tt -77.5 -20.41 54.32 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.556 -0.715 . . . . 0.0 110.214 179.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -70.67 -31.04 67.81 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.363 -0.836 . . . . 0.0 110.264 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 7.4 mt -82.34 -26.3 33.08 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.359 -0.838 . . . . 0.0 110.201 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -82.81 -32.18 27.57 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.56 -31.7 71.74 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.26 -1.141 . . . . 0.0 110.245 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 63.1 tp -77.28 -48.14 18.24 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.332 -0.855 . . . . 0.0 110.123 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.415 ' HA ' HG12 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -56.79 -34.03 67.25 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.404 -0.81 . . . . 0.0 110.325 179.962 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -71.78 -34.35 69.36 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.417 -0.802 . . . . 0.0 109.998 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 3.7 tp -70.01 -29.91 67.08 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.412 -0.805 . . . . 0.0 110.214 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.415 HG12 ' HA ' ' A' ' 15' ' ' LYS . 22.4 pt -90.82 -22.01 6.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.346 -0.846 . . . . 0.0 110.397 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 9.4 mmtm -82.66 -172.69 4.21 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.287 -0.883 . . . . 0.0 110.248 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.346 0 O-C-N 119.886 -1.759 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.217 -0.633 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.7 pt -116.8 27.48 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.389 -0.819 . . . . 0.0 110.262 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.2 t80 -55.91 -42.64 76.36 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.28 -0.888 . . . . 0.0 110.353 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.481 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -61.59 -18.8 57.04 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.02 -15.82 27.33 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.296 -1.12 . . . . 0.0 110.541 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 48.0 mm -84.99 -32.79 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.244 -0.91 . . . . 0.0 110.315 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.465 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -65.24 -51.54 53.12 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 121.357 -0.839 . . . . 0.0 110.194 -179.917 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.481 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 38.0 Cg_exo -54.61 -28.19 54.63 Favored 'Trans proline' 0 C--N 1.314 -1.285 0 O-C-N 123.485 1.255 . . . . 0.0 110.13 179.491 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 12.0 tp -82.71 -27.76 30.99 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.392 -0.817 . . . . 0.0 110.079 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -63.08 -33.37 75.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.42 -0.8 . . . . 0.0 110.02 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.8 mt -74.19 -28.57 61.34 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.522 -0.736 . . . . 0.0 110.117 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -76.25 -31.71 54.13 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -59.19 -29.0 67.15 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.419 -1.047 . . . . 0.0 109.964 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 31.3 tp -78.6 -50.11 12.09 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.474 -0.766 . . . . 0.0 110.014 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.431 ' HA ' ' CG1' ' A' ' 18' ' ' ILE . 0.0 OUTLIER -58.0 -27.3 63.38 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.331 -0.856 . . . . 0.0 110.172 -179.957 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -73.09 -36.6 66.83 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.376 -0.827 . . . . 0.0 110.038 179.753 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 13.8 tp -72.15 -37.7 69.35 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.389 -0.819 . . . . 0.0 110.021 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.431 ' CG1' ' HA ' ' A' ' 15' ' ' LYS . 1.3 pp -88.56 -22.02 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.49 -0.756 . . . . 0.0 110.382 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -167.41 82.87 0.21 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.269 -0.894 . . . . 0.0 110.24 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.346 0 O-C-N 119.902 -1.749 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.696 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 5.7 pt -136.93 26.46 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.298 -0.876 . . . . 0.0 110.423 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -62.54 -37.85 87.71 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.42 -0.8 . . . . 0.0 110.087 179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.491 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -60.73 -19.71 55.55 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.772 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.516 ' O ' HD12 ' A' ' 9' ' ' LEU . . . -89.43 -18.27 27.13 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.28 -1.129 . . . . 0.0 110.294 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 49.4 mm -83.15 -33.55 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.229 -0.92 . . . . 0.0 110.397 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.448 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -62.27 -51.89 70.62 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.372 -0.83 . . . . 0.0 110.238 -179.84 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.491 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 31.8 Cg_exo -52.12 -31.43 45.03 Favored 'Trans proline' 0 C--N 1.315 -1.197 0 O-C-N 123.426 1.224 . . . . 0.0 110.222 179.487 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.516 HD12 ' O ' ' A' ' 5' ' ' ALA . 18.3 mt -77.77 -25.88 49.38 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.444 -0.785 . . . . 0.0 110.029 179.623 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -68.93 -29.17 67.37 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.346 -0.846 . . . . 0.0 110.226 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 6.8 mt -77.39 -24.35 50.55 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.428 -0.795 . . . . 0.0 110.267 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -79.83 -33.78 32.74 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.649 -1.381 . . . . 0.0 109.649 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.23 -32.13 71.92 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.316 -1.108 . . . . 0.0 109.971 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 28.4 tp -78.39 -50.43 11.74 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.486 -0.759 . . . . 0.0 109.867 179.643 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.443 ' HA ' HG12 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -56.34 -27.97 57.53 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.552 -0.718 . . . . 0.0 110.391 179.947 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 -77.96 -29.23 49.71 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.419 -0.801 . . . . 0.0 110.007 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 tt -76.79 -27.51 55.27 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.367 -0.833 . . . . 0.0 110.276 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.443 HG12 ' HA ' ' A' ' 15' ' ' LYS . 13.6 pt -91.37 -21.93 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.24 -0.912 . . . . 0.0 110.43 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.5 tmtm? -110.46 97.17 6.68 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.353 -0.842 . . . . 0.0 110.259 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.362 0 O-C-N 119.858 -1.776 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.707 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.628 ' O ' HG22 ' A' ' 2' ' ' ILE . 75.9 mt -106.26 25.3 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.371 -0.831 . . . . 0.0 110.207 . . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.462 ' HA ' HD12 ' A' ' 6' ' ' ILE . 48.1 t80 -67.14 -37.59 84.07 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.26 -0.9 . . . . 0.0 110.156 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.487 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -61.96 -18.18 56.64 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HB3' HG22 ' A' ' 2' ' ' ILE . . . -91.72 -20.23 21.78 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.269 -1.136 . . . . 0.0 110.44 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.462 HD12 ' HA ' ' A' ' 3' ' ' PHE . 76.0 mt -83.94 -28.14 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.226 -0.921 . . . . 0.0 110.452 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.487 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -67.74 -52.02 27.62 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.221 -0.925 . . . . 0.0 110.134 179.958 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.487 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 38.2 Cg_exo -54.69 -26.77 48.39 Favored 'Trans proline' 0 C--N 1.312 -1.371 0 O-C-N 123.515 1.271 . . . . 0.0 110.172 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.698 HD23 ' O ' ' A' ' 9' ' ' LEU . 3.2 tt -77.74 -28.13 50.68 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.439 -0.788 . . . . 0.0 110.003 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -67.69 -43.64 79.63 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.434 -0.791 . . . . 0.0 110.176 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 5.2 mt -72.39 -29.06 63.4 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.591 -0.693 . . . . 0.0 110.237 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.43 ' O ' ' ND2' ' A' ' 16' ' ' ASN . . . -68.7 -33.77 76.67 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.531 ' O ' HD23 ' A' ' 17' ' ' LEU . . . -61.74 -29.33 70.04 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.314 -1.109 . . . . 0.0 110.125 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 49.1 tp -81.47 -48.59 11.67 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.369 -0.832 . . . . 0.0 110.072 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.479 ' HA ' ' CG1' ' A' ' 18' ' ' ILE . 0.0 OUTLIER -60.63 -22.63 64.02 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.401 -0.812 . . . . 0.0 110.454 179.978 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASN . . . . . 0.43 ' ND2' ' O ' ' A' ' 12' ' ' GLY . 17.3 m-80 -75.31 -37.18 60.92 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.3 -0.875 . . . . 0.0 110.422 -179.739 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.531 HD23 ' O ' ' A' ' 13' ' ' ALA . 4.3 mm? -74.64 -32.65 62.34 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.307 -0.87 . . . . 0.0 110.296 -179.7 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.479 ' CG1' ' HA ' ' A' ' 15' ' ' LYS . 1.3 pp -89.07 -21.73 6.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.406 -0.809 . . . . 0.0 110.416 -179.796 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 8.4 tttt -121.51 -160.75 0.87 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.308 -0.87 . . . . 0.0 110.15 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.31 0 O-C-N 119.767 -1.833 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.67 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.6 pt -104.84 29.86 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.367 -0.833 . . . . 0.0 110.246 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -74.8 -37.18 62.43 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.451 -0.781 . . . . 0.0 110.188 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.481 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -64.94 -15.96 61.09 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.73 -21.67 20.6 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.241 -1.152 . . . . 0.0 110.368 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 91.3 mt -83.02 -30.11 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.242 -0.911 . . . . 0.0 110.473 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.476 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -65.37 -52.79 43.44 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.362 -0.836 . . . . 0.0 110.11 179.927 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.481 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 31.2 Cg_exo -52.26 -29.09 36.7 Favored 'Trans proline' 0 C--N 1.314 -1.259 0 O-C-N 123.463 1.244 . . . . 0.0 110.276 179.45 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 10.7 tp -77.37 -27.61 52.63 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.438 -0.789 . . . . 0.0 110.032 179.686 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -74.09 -32.43 63.24 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.325 -0.859 . . . . 0.0 109.997 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 1.3 mt -78.65 -27.69 45.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.503 -0.748 . . . . 0.0 110.149 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -78.06 -32.98 42.3 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.06 -28.41 69.04 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.36 -1.082 . . . . 0.0 110.095 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 51.5 tp -78.63 -50.65 11.12 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.441 -0.787 . . . . 0.0 110.064 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.417 ' HA ' HG12 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -57.09 -33.3 67.16 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.307 -0.871 . . . . 0.0 110.18 179.998 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -68.84 -37.25 79.02 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.445 -0.784 . . . . 0.0 110.138 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 2.6 tp -67.78 -34.11 76.16 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.281 -0.887 . . . . 0.0 110.193 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.417 HG12 ' HA ' ' A' ' 15' ' ' LYS . 22.3 pt -91.21 -23.32 5.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.463 -0.773 . . . . 0.0 110.543 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.41 ' N ' HG13 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -112.2 -60.6 1.84 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.219 -0.925 . . . . 0.0 110.229 179.971 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.363 0 O-C-N 119.871 -1.768 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.669 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.598 ' O ' HG22 ' A' ' 2' ' ' ILE . 79.1 mt -96.78 16.93 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.312 -0.868 . . . . 0.0 110.369 . . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.3 t80 -61.72 -39.36 91.27 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.209 -0.932 . . . . 0.0 110.11 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.471 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -60.36 -19.46 53.0 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.747 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.423 ' HB3' HG22 ' A' ' 2' ' ' ILE . . . -90.88 -13.6 33.35 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.391 -1.064 . . . . 0.0 110.508 179.846 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 49.1 mm -84.98 -38.91 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.269 -0.894 . . . . 0.0 110.242 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.464 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -60.59 -51.0 82.88 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.368 -0.832 . . . . 0.0 110.516 -179.777 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.471 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 35.7 Cg_exo -55.42 -28.73 65.11 Favored 'Trans proline' 0 C--N 1.314 -1.252 0 O-C-N 123.375 1.197 . . . . 0.0 110.323 179.631 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -79.61 -25.21 41.52 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.477 -0.764 . . . . 0.0 110.255 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -62.32 -33.74 75.27 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.31 -0.869 . . . . 0.0 110.141 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 1.2 mt -75.54 -27.37 58.63 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.411 -0.806 . . . . 0.0 110.206 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -79.04 -31.29 43.58 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.567 ' O ' HD23 ' A' ' 17' ' ' LEU . . . -61.14 -26.92 68.02 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.365 -1.079 . . . . 0.0 109.965 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 29.3 tp -81.05 -50.55 9.52 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.376 -0.827 . . . . 0.0 109.994 179.829 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.458 ' HA ' ' CG1' ' A' ' 18' ' ' ILE . 0.0 OUTLIER -58.35 -26.29 62.96 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.487 -0.758 . . . . 0.0 110.434 -179.829 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.5 m-20 -72.18 -36.72 69.34 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.38 -0.825 . . . . 0.0 110.487 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.567 HD23 ' O ' ' A' ' 13' ' ' ALA . 4.2 mm? -72.98 -36.46 67.09 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.301 -0.874 . . . . 0.0 110.395 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.458 ' CG1' ' HA ' ' A' ' 15' ' ' LYS . 3.7 pt -85.33 -10.4 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.474 -0.766 . . . . 0.0 110.564 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.8 tptt -60.48 147.27 41.78 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.182 -0.949 . . . . 0.0 110.281 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.382 0 O-C-N 119.884 -1.76 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.69 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 4.5 pt -118.86 29.79 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.383 -0.823 . . . . 0.0 110.343 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 33.1 t80 -61.34 -38.83 88.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.384 -0.823 . . . . 0.0 110.187 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.481 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -62.28 -17.81 56.88 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.614 -1.395 . . . . 0.0 109.614 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.11 -15.79 27.24 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.323 -1.104 . . . . 0.0 110.482 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 48.3 mm -85.4 -33.89 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.28 -0.888 . . . . 0.0 110.32 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.478 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -64.45 -51.81 57.54 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.315 -0.865 . . . . 0.0 110.218 -179.847 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.481 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 38.8 Cg_exo -54.88 -28.46 58.68 Favored 'Trans proline' 0 C--N 1.314 -1.254 0 O-C-N 123.357 1.188 . . . . 0.0 110.196 179.483 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -80.25 -27.32 38.69 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.461 -0.774 . . . . 0.0 110.005 179.672 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -73.04 -28.41 62.31 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.386 -0.821 . . . . 0.0 110.062 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.6 mt -78.85 -27.43 44.17 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.418 -0.801 . . . . 0.0 110.199 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -79.3 -35.34 30.1 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.559 ' O ' HD23 ' A' ' 17' ' ' LEU . . . -60.03 -27.46 66.93 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.338 -1.095 . . . . 0.0 110.091 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 58.0 tp -81.88 -48.22 11.8 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.406 -0.809 . . . . 0.0 109.983 179.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.444 ' HA ' ' CG1' ' A' ' 18' ' ' ILE . 0.0 OUTLIER -58.34 -27.86 64.55 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.422 -0.799 . . . . 0.0 110.223 179.985 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 90.7 m-20 -70.29 -35.48 73.74 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.349 -0.844 . . . . 0.0 110.459 -179.799 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.559 HD23 ' O ' ' A' ' 13' ' ' ALA . 4.3 mm? -74.71 -36.76 62.71 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.278 -0.889 . . . . 0.0 110.287 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.444 ' CG1' ' HA ' ' A' ' 15' ' ' LYS . 2.4 pt -89.86 -18.62 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.498 -0.752 . . . . 0.0 110.517 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -146.49 44.74 1.21 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.226 -0.922 . . . . 0.0 110.261 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.354 0 O-C-N 119.927 -1.733 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.696 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.616 ' O ' HG22 ' A' ' 2' ' ' ILE . 73.8 mt 53.13 25.08 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.305 -0.872 . . . . 0.0 110.516 . . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.518 ' HA ' HD12 ' A' ' 6' ' ' ILE . 50.7 t80 -65.64 -38.65 89.98 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.261 -0.9 . . . . 0.0 110.12 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.488 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -60.95 -19.13 56.01 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.58 ' HB3' HG22 ' A' ' 2' ' ' ILE . . . -90.01 -22.06 22.07 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.256 -1.144 . . . . 0.0 110.36 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.518 HD12 ' HA ' ' A' ' 3' ' ' PHE . 72.7 mt -83.89 -28.6 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.293 -0.88 . . . . 0.0 110.419 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.475 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -64.72 -52.72 49.13 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 121.248 -0.908 . . . . 0.0 110.203 -179.862 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.488 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 33.3 Cg_exo -52.85 -32.03 54.68 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.561 1.295 . . . . 0.0 110.076 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.453 ' HA ' HD13 ' A' ' 9' ' ' LEU . 2.1 mm? -78.63 -27.36 45.38 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.445 -0.784 . . . . 0.0 109.909 179.737 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.41 -43.3 91.01 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.413 -0.804 . . . . 0.0 110.075 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 6.7 mt -67.54 -26.27 66.23 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.432 -0.792 . . . . 0.0 110.157 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -72.12 -34.36 61.52 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.381 -1.487 . . . . 0.0 109.381 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -58.41 -28.12 64.93 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.436 -1.038 . . . . 0.0 110.307 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 62.3 tp -79.0 -46.55 17.96 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.359 -0.838 . . . . 0.0 109.96 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.564 ' HE2' HD11 ' A' ' 18' ' ' ILE . 4.9 mmpt? -61.36 -30.71 70.7 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.443 -0.786 . . . . 0.0 109.922 -179.678 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 68.2 m-20 -76.03 -30.49 58.47 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.4 -0.812 . . . . 0.0 109.832 179.703 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 tt -71.8 -30.34 65.41 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.417 -0.802 . . . . 0.0 110.118 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.564 HD11 ' HE2' ' A' ' 15' ' ' LYS . 12.7 pt -84.3 -21.69 8.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.445 -0.784 . . . . 0.0 110.434 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.406 ' N ' HG13 ' A' ' 18' ' ' ILE . 2.0 tmtt? -104.04 139.26 39.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.245 -0.909 . . . . 0.0 110.166 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.383 0 O-C-N 119.812 -1.805 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.709 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.585 ' O ' HG22 ' A' ' 2' ' ' ILE . 3.1 mp -118.22 14.39 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.337 -0.852 . . . . 0.0 110.472 . . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.439 ' HA ' HD12 ' A' ' 6' ' ' ILE . 58.4 t80 -63.58 -33.12 74.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.136 -0.978 . . . . 0.0 109.879 179.745 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.49 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -63.47 -16.46 58.52 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.616 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.82 -22.12 22.25 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.232 -1.158 . . . . 0.0 110.281 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.439 HD12 ' HA ' ' A' ' 3' ' ' PHE . 79.3 mt -83.16 -30.28 8.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.222 -0.923 . . . . 0.0 110.407 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.475 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -63.44 -52.52 59.67 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.281 -0.887 . . . . 0.0 110.36 -179.908 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.49 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 32.8 Cg_exo -52.81 -31.4 51.45 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 O-C-N 123.347 1.183 . . . . 0.0 110.339 179.614 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.504 HD23 ' O ' ' A' ' 9' ' ' LEU . 2.0 tt -76.96 -27.18 54.7 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.425 -0.797 . . . . 0.0 109.92 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.54 -41.54 92.93 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.428 -0.795 . . . . 0.0 109.969 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 33.2 mt -75.03 -28.91 60.64 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.545 -0.722 . . . . 0.0 110.051 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.54 -32.03 74.47 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -66.34 -26.05 67.1 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.296 -1.12 . . . . 0.0 110.001 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.467 ' O ' HG23 ' A' ' 18' ' ' ILE . 63.2 tp -80.37 -45.93 16.92 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.411 -0.806 . . . . 0.0 110.276 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.411 ' HA ' HG12 ' A' ' 18' ' ' ILE . 3.8 mmpt? -68.55 -26.53 65.46 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.345 -0.847 . . . . 0.0 110.002 -179.662 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 3.3 m-20 -81.38 -26.64 35.33 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.295 -0.878 . . . . 0.0 109.656 179.661 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 8.3 tt -77.23 -27.2 53.26 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.476 -0.765 . . . . 0.0 110.243 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.467 HG23 ' O ' ' A' ' 14' ' ' LEU . 14.2 pt -79.76 -21.9 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.322 -0.861 . . . . 0.0 110.331 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.407 ' N ' HG13 ' A' ' 18' ' ' ILE . 2.6 mttt -169.95 72.61 0.07 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.243 -0.911 . . . . 0.0 110.245 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.34 0 O-C-N 119.855 -1.778 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.688 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.618 ' O ' HG22 ' A' ' 2' ' ' ILE . 47.9 mt -112.15 20.59 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.317 -0.865 . . . . 0.0 110.097 . . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PHE . . . . . 0.405 ' HA ' HD12 ' A' ' 6' ' ' ILE . 46.7 t80 -64.85 -36.41 84.26 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.238 -0.914 . . . . 0.0 109.995 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.487 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -61.98 -18.11 56.55 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 179.857 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.461 ' HB3' HG22 ' A' ' 2' ' ' ILE . . . -90.16 -21.36 22.25 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.307 -1.114 . . . . 0.0 110.278 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ILE . . . . . 0.405 HD12 ' HA ' ' A' ' 3' ' ' PHE . 82.0 mt -83.34 -29.6 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.31 -0.868 . . . . 0.0 110.437 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.473 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -64.39 -52.37 53.98 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.204 -0.935 . . . . 0.0 110.293 -179.916 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.487 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 31.7 Cg_exo -52.48 -31.84 50.27 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 O-C-N 123.485 1.255 . . . . 0.0 110.093 179.556 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.427 HD23 ' O ' ' A' ' 9' ' ' LEU . 0.9 OUTLIER -78.92 -23.73 44.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.425 -0.797 . . . . 0.0 110.044 179.679 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -71.15 -29.67 65.5 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.316 -0.865 . . . . 0.0 110.225 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 79.1 mt -82.09 -27.79 32.68 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.322 -0.861 . . . . 0.0 110.274 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -77.97 -34.57 37.65 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.584 ' O ' HD23 ' A' ' 17' ' ' LEU . . . -64.17 -25.55 68.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.408 -1.054 . . . . 0.0 110.134 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 62.9 tp -85.33 -46.54 10.88 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.345 -0.847 . . . . 0.0 110.035 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.695 ' HE2' HD11 ' A' ' 18' ' ' ILE . 4.2 mmpt? -64.31 -21.39 66.59 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.526 -0.734 . . . . 0.0 110.051 -179.813 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -76.58 -36.92 57.27 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.322 -0.861 . . . . 0.0 110.185 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.584 HD23 ' O ' ' A' ' 13' ' ' ALA . 4.2 mm? -73.43 -34.4 65.42 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.356 -0.84 . . . . 0.0 110.124 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.695 HD11 ' HE2' ' A' ' 15' ' ' LYS . 1.7 pp -90.93 -22.43 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.514 -0.741 . . . . 0.0 110.399 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.1 tmtt? -137.62 97.63 3.49 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.208 -0.933 . . . . 0.0 110.152 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.282 0 O-C-N 119.798 -1.814 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.214 -0.769 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.8 pt -121.62 24.9 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.336 -0.853 . . . . 0.0 110.271 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -69.64 -45.33 68.72 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.242 -0.911 . . . . 0.0 109.872 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.482 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -67.83 -9.05 55.4 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 179.264 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.23 -27.69 18.29 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.294 -1.121 . . . . 0.0 110.232 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 46.5 mm -82.62 -31.39 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.263 -0.898 . . . . 0.0 110.408 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' TRP . . . . . 0.464 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -61.33 -52.46 70.53 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 121.303 -0.873 . . . . 0.0 110.612 -179.699 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.482 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 31.3 Cg_exo -52.39 -33.59 57.18 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 O-C-N 123.352 1.185 . . . . 0.0 110.288 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.0 tt -77.5 -20.41 54.32 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.556 -0.715 . . . . 0.0 110.214 179.678 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -70.67 -31.04 67.81 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.363 -0.836 . . . . 0.0 110.264 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 7.4 mt -82.34 -26.3 33.08 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.359 -0.838 . . . . 0.0 110.201 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -82.81 -32.18 27.57 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.56 -31.7 71.74 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.26 -1.141 . . . . 0.0 110.245 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 63.1 tp -77.28 -48.14 18.24 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.332 -0.855 . . . . 0.0 110.123 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.465 ' HA ' HG12 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -56.79 -34.03 67.25 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.404 -0.81 . . . . 0.0 110.325 179.962 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -71.78 -34.35 69.36 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.417 -0.802 . . . . 0.0 109.998 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 3.7 tp -70.01 -29.91 67.08 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.412 -0.805 . . . . 0.0 110.214 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.465 HG12 ' HA ' ' A' ' 15' ' ' LYS . 22.4 pt -90.82 -22.01 6.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.346 -0.846 . . . . 0.0 110.397 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 9.4 mmtm -82.66 -172.69 4.21 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.287 -0.883 . . . . 0.0 110.248 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.346 0 O-C-N 119.886 -1.759 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.217 -0.633 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.7 pt -116.8 27.48 3.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.389 -0.819 . . . . 0.0 110.262 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 36.2 t80 -55.91 -42.64 76.36 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.28 -0.888 . . . . 0.0 110.353 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.481 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -61.59 -18.8 57.04 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.02 -15.82 27.33 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.296 -1.12 . . . . 0.0 110.541 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 48.0 mm -84.99 -32.79 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.244 -0.91 . . . . 0.0 110.315 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.465 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -65.24 -51.54 53.12 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 121.357 -0.839 . . . . 0.0 110.194 -179.917 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.481 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 38.0 Cg_exo -54.61 -28.19 54.63 Favored 'Trans proline' 0 C--N 1.314 -1.285 0 O-C-N 123.485 1.255 . . . . 0.0 110.13 179.491 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 12.0 tp -82.71 -27.76 30.99 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.392 -0.817 . . . . 0.0 110.079 179.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -63.08 -33.37 75.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.42 -0.8 . . . . 0.0 110.02 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 12.8 mt -74.19 -28.57 61.34 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.522 -0.736 . . . . 0.0 110.117 179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -76.25 -31.71 54.13 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -59.19 -29.0 67.15 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.419 -1.047 . . . . 0.0 109.964 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 31.3 tp -78.6 -50.11 12.09 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.474 -0.766 . . . . 0.0 110.014 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.431 ' HA ' ' CG1' ' A' ' 18' ' ' ILE . 0.0 OUTLIER -58.0 -27.3 63.38 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.331 -0.856 . . . . 0.0 110.172 -179.957 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -73.09 -36.6 66.83 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.376 -0.827 . . . . 0.0 110.038 179.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 13.8 tp -72.15 -37.7 69.35 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.389 -0.819 . . . . 0.0 110.021 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.431 ' CG1' ' HA ' ' A' ' 15' ' ' LYS . 1.3 pp -88.56 -22.02 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.49 -0.756 . . . . 0.0 110.382 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -167.41 82.87 0.21 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.269 -0.894 . . . . 0.0 110.24 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.346 0 O-C-N 119.902 -1.749 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.696 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 5.7 pt -136.93 26.46 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.298 -0.876 . . . . 0.0 110.423 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -62.54 -37.85 87.71 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.42 -0.8 . . . . 0.0 110.087 179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.491 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -60.73 -19.71 55.55 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.516 ' O ' HD12 ' A' ' 9' ' ' LEU . . . -89.43 -18.27 27.13 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.28 -1.129 . . . . 0.0 110.294 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 49.4 mm -83.15 -33.55 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.229 -0.92 . . . . 0.0 110.397 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.448 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -62.27 -51.89 70.62 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.372 -0.83 . . . . 0.0 110.238 -179.84 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.491 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 31.8 Cg_exo -52.12 -31.43 45.03 Favored 'Trans proline' 0 C--N 1.315 -1.197 0 O-C-N 123.426 1.224 . . . . 0.0 110.222 179.487 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.516 HD12 ' O ' ' A' ' 5' ' ' ALA . 18.3 mt -77.77 -25.88 49.38 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.444 -0.785 . . . . 0.0 110.029 179.623 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -68.93 -29.17 67.37 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.346 -0.846 . . . . 0.0 110.226 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 6.8 mt -77.39 -24.35 50.55 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.428 -0.795 . . . . 0.0 110.267 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -79.83 -33.78 32.74 Favored Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.649 -1.381 . . . . 0.0 109.649 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.23 -32.13 71.92 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.316 -1.108 . . . . 0.0 109.971 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 28.4 tp -78.39 -50.43 11.74 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.486 -0.759 . . . . 0.0 109.867 179.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.443 ' HA ' HG12 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -56.34 -27.97 57.53 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.552 -0.718 . . . . 0.0 110.391 179.947 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 -77.96 -29.23 49.71 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.419 -0.801 . . . . 0.0 110.007 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 tt -76.79 -27.51 55.27 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.367 -0.833 . . . . 0.0 110.276 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.443 HG12 ' HA ' ' A' ' 15' ' ' LYS . 13.6 pt -91.37 -21.93 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.24 -0.912 . . . . 0.0 110.43 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.5 tmtm? -110.46 97.17 6.68 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.353 -0.842 . . . . 0.0 110.259 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.362 0 O-C-N 119.858 -1.776 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.707 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.628 ' O ' HG22 ' A' ' 2' ' ' ILE . 75.9 mt -106.26 25.3 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.371 -0.831 . . . . 0.0 110.207 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.462 ' HA ' HD12 ' A' ' 6' ' ' ILE . 48.1 t80 -67.14 -37.59 84.07 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.26 -0.9 . . . . 0.0 110.156 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.487 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -61.96 -18.18 56.64 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HB3' HG22 ' A' ' 2' ' ' ILE . . . -91.72 -20.23 21.78 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.269 -1.136 . . . . 0.0 110.44 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.462 HD12 ' HA ' ' A' ' 3' ' ' PHE . 76.0 mt -83.94 -28.14 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.226 -0.921 . . . . 0.0 110.452 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.487 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -67.74 -52.02 27.62 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.221 -0.925 . . . . 0.0 110.134 179.958 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.487 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 38.2 Cg_exo -54.69 -26.77 48.39 Favored 'Trans proline' 0 C--N 1.312 -1.371 0 O-C-N 123.515 1.271 . . . . 0.0 110.172 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.698 HD23 ' O ' ' A' ' 9' ' ' LEU . 3.2 tt -77.74 -28.13 50.68 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.439 -0.788 . . . . 0.0 110.003 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -67.69 -43.64 79.63 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.434 -0.791 . . . . 0.0 110.176 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 5.2 mt -72.39 -29.06 63.4 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.591 -0.693 . . . . 0.0 110.237 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.7 -33.77 76.67 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.531 ' O ' HD23 ' A' ' 17' ' ' LEU . . . -61.74 -29.33 70.04 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.314 -1.109 . . . . 0.0 110.125 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 49.1 tp -81.47 -48.59 11.67 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.369 -0.832 . . . . 0.0 110.072 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.479 ' HA ' ' CG1' ' A' ' 18' ' ' ILE . 0.0 OUTLIER -60.63 -22.63 64.02 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.401 -0.812 . . . . 0.0 110.454 179.978 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -75.31 -37.18 60.92 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.3 -0.875 . . . . 0.0 110.422 -179.739 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.531 HD23 ' O ' ' A' ' 13' ' ' ALA . 4.3 mm? -74.64 -32.65 62.34 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.307 -0.87 . . . . 0.0 110.296 -179.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.479 ' CG1' ' HA ' ' A' ' 15' ' ' LYS . 1.3 pp -89.07 -21.73 6.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.406 -0.809 . . . . 0.0 110.416 -179.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 8.4 tttt -121.51 -160.75 0.87 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.308 -0.87 . . . . 0.0 110.15 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.31 0 O-C-N 119.767 -1.833 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.67 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.6 pt -104.84 29.86 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.367 -0.833 . . . . 0.0 110.246 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -74.8 -37.18 62.43 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.451 -0.781 . . . . 0.0 110.188 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.481 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -64.94 -15.96 61.09 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.73 -21.67 20.6 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.241 -1.152 . . . . 0.0 110.368 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 91.3 mt -83.02 -30.11 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.242 -0.911 . . . . 0.0 110.473 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.476 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -65.37 -52.79 43.44 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.362 -0.836 . . . . 0.0 110.11 179.927 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.481 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 31.2 Cg_exo -52.26 -29.09 36.7 Favored 'Trans proline' 0 C--N 1.314 -1.259 0 O-C-N 123.463 1.244 . . . . 0.0 110.276 179.45 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 10.7 tp -77.37 -27.61 52.63 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.438 -0.789 . . . . 0.0 110.032 179.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -74.09 -32.43 63.24 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.325 -0.859 . . . . 0.0 109.997 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 1.3 mt -78.65 -27.69 45.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.503 -0.748 . . . . 0.0 110.149 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -78.06 -32.98 42.3 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.06 -28.41 69.04 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.36 -1.082 . . . . 0.0 110.095 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 51.5 tp -78.63 -50.65 11.12 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.441 -0.787 . . . . 0.0 110.064 179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.417 ' HA ' HG12 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -57.09 -33.3 67.16 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.307 -0.871 . . . . 0.0 110.18 179.998 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -68.84 -37.25 79.02 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.445 -0.784 . . . . 0.0 110.138 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 2.6 tp -67.78 -34.11 76.16 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.281 -0.887 . . . . 0.0 110.193 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.417 HG12 ' HA ' ' A' ' 15' ' ' LYS . 22.3 pt -91.21 -23.32 5.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.463 -0.773 . . . . 0.0 110.543 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.41 ' N ' HG13 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -112.2 -60.6 1.84 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.219 -0.925 . . . . 0.0 110.229 179.971 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.363 0 O-C-N 119.871 -1.768 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.669 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.598 ' O ' HG22 ' A' ' 2' ' ' ILE . 79.1 mt -96.78 16.93 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.312 -0.868 . . . . 0.0 110.369 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 63.3 t80 -61.72 -39.36 91.27 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.209 -0.932 . . . . 0.0 110.11 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.471 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -60.36 -19.46 53.0 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.747 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.423 ' HB3' HG22 ' A' ' 2' ' ' ILE . . . -90.88 -13.6 33.35 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.391 -1.064 . . . . 0.0 110.508 179.846 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 49.1 mm -84.98 -38.91 13.67 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.269 -0.894 . . . . 0.0 110.242 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.464 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -60.59 -51.0 82.88 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.368 -0.832 . . . . 0.0 110.516 -179.777 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.471 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 35.7 Cg_exo -55.42 -28.73 65.11 Favored 'Trans proline' 0 C--N 1.314 -1.252 0 O-C-N 123.375 1.197 . . . . 0.0 110.323 179.631 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -79.61 -25.21 41.52 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.477 -0.764 . . . . 0.0 110.255 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -62.32 -33.74 75.27 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.31 -0.869 . . . . 0.0 110.141 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 1.2 mt -75.54 -27.37 58.63 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.411 -0.806 . . . . 0.0 110.206 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -79.04 -31.29 43.58 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.567 ' O ' HD23 ' A' ' 17' ' ' LEU . . . -61.14 -26.92 68.02 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.365 -1.079 . . . . 0.0 109.965 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 29.3 tp -81.05 -50.55 9.52 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.376 -0.827 . . . . 0.0 109.994 179.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.458 ' HA ' ' CG1' ' A' ' 18' ' ' ILE . 0.0 OUTLIER -58.35 -26.29 62.96 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.487 -0.758 . . . . 0.0 110.434 -179.829 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 43.5 m-20 -72.18 -36.72 69.34 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.38 -0.825 . . . . 0.0 110.487 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.567 HD23 ' O ' ' A' ' 13' ' ' ALA . 4.2 mm? -72.98 -36.46 67.09 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.301 -0.874 . . . . 0.0 110.395 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.458 ' CG1' ' HA ' ' A' ' 15' ' ' LYS . 3.7 pt -85.33 -10.4 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.474 -0.766 . . . . 0.0 110.564 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.8 tptt -60.48 147.27 41.78 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.182 -0.949 . . . . 0.0 110.281 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.382 0 O-C-N 119.884 -1.76 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.69 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 4.5 pt -118.86 29.79 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.383 -0.823 . . . . 0.0 110.343 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 33.1 t80 -61.34 -38.83 88.34 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.384 -0.823 . . . . 0.0 110.187 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.481 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -62.28 -17.81 56.88 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.614 -1.395 . . . . 0.0 109.614 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -92.11 -15.79 27.24 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.323 -1.104 . . . . 0.0 110.482 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 48.3 mm -85.4 -33.89 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.28 -0.888 . . . . 0.0 110.32 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.478 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -64.45 -51.81 57.54 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.315 -0.865 . . . . 0.0 110.218 -179.847 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.481 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 38.8 Cg_exo -54.88 -28.46 58.68 Favored 'Trans proline' 0 C--N 1.314 -1.254 0 O-C-N 123.357 1.188 . . . . 0.0 110.196 179.483 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -80.25 -27.32 38.69 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.461 -0.774 . . . . 0.0 110.005 179.672 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -73.04 -28.41 62.31 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.386 -0.821 . . . . 0.0 110.062 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.6 mt -78.85 -27.43 44.17 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.418 -0.801 . . . . 0.0 110.199 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -79.3 -35.34 30.1 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.559 ' O ' HD23 ' A' ' 17' ' ' LEU . . . -60.03 -27.46 66.93 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.338 -1.095 . . . . 0.0 110.091 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 58.0 tp -81.88 -48.22 11.8 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.406 -0.809 . . . . 0.0 109.983 179.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.444 ' HA ' ' CG1' ' A' ' 18' ' ' ILE . 0.0 OUTLIER -58.34 -27.86 64.55 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.422 -0.799 . . . . 0.0 110.223 179.985 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 90.7 m-20 -70.29 -35.48 73.74 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.349 -0.844 . . . . 0.0 110.459 -179.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.559 HD23 ' O ' ' A' ' 13' ' ' ALA . 4.3 mm? -74.71 -36.76 62.71 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.278 -0.889 . . . . 0.0 110.287 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.444 ' CG1' ' HA ' ' A' ' 15' ' ' LYS . 2.4 pt -89.86 -18.62 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.498 -0.752 . . . . 0.0 110.517 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -146.49 44.74 1.21 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.226 -0.922 . . . . 0.0 110.261 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.354 0 O-C-N 119.927 -1.733 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.696 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.616 ' O ' HG22 ' A' ' 2' ' ' ILE . 73.8 mt 53.13 25.08 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.305 -0.872 . . . . 0.0 110.516 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.518 ' HA ' HD12 ' A' ' 6' ' ' ILE . 50.7 t80 -65.64 -38.65 89.98 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.261 -0.9 . . . . 0.0 110.12 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.488 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -60.95 -19.13 56.01 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.58 ' HB3' HG22 ' A' ' 2' ' ' ILE . . . -90.01 -22.06 22.07 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.256 -1.144 . . . . 0.0 110.36 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.518 HD12 ' HA ' ' A' ' 3' ' ' PHE . 72.7 mt -83.89 -28.6 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.293 -0.88 . . . . 0.0 110.419 -179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.475 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -64.72 -52.72 49.13 Favored Pre-proline 0 N--CA 1.493 1.694 0 O-C-N 121.248 -0.908 . . . . 0.0 110.203 -179.862 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.488 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 33.3 Cg_exo -52.85 -32.03 54.68 Favored 'Trans proline' 0 C--N 1.312 -1.344 0 O-C-N 123.561 1.295 . . . . 0.0 110.076 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.453 ' HA ' HD13 ' A' ' 9' ' ' LEU . 2.1 mm? -78.63 -27.36 45.38 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.445 -0.784 . . . . 0.0 109.909 179.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.41 -43.3 91.01 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.413 -0.804 . . . . 0.0 110.075 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 6.7 mt -67.54 -26.27 66.23 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.432 -0.792 . . . . 0.0 110.157 179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -72.12 -34.36 61.52 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.381 -1.487 . . . . 0.0 109.381 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -58.41 -28.12 64.93 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.436 -1.038 . . . . 0.0 110.307 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 62.3 tp -79.0 -46.55 17.96 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.359 -0.838 . . . . 0.0 109.96 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.564 ' HE2' HD11 ' A' ' 18' ' ' ILE . 4.9 mmpt? -61.36 -30.71 70.7 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.443 -0.786 . . . . 0.0 109.922 -179.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 68.2 m-20 -76.03 -30.49 58.47 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.4 -0.812 . . . . 0.0 109.832 179.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 tt -71.8 -30.34 65.41 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.417 -0.802 . . . . 0.0 110.118 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.564 HD11 ' HE2' ' A' ' 15' ' ' LYS . 12.7 pt -84.3 -21.69 8.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.445 -0.784 . . . . 0.0 110.434 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.406 ' N ' HG13 ' A' ' 18' ' ' ILE . 2.0 tmtt? -104.04 139.26 39.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.245 -0.909 . . . . 0.0 110.166 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.383 0 O-C-N 119.812 -1.805 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.709 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.585 ' O ' HG22 ' A' ' 2' ' ' ILE . 3.1 mp -118.22 14.39 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.337 -0.852 . . . . 0.0 110.472 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.439 ' HA ' HD12 ' A' ' 6' ' ' ILE . 58.4 t80 -63.58 -33.12 74.89 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.136 -0.978 . . . . 0.0 109.879 179.745 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.49 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -63.47 -16.46 58.52 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.616 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -89.82 -22.12 22.25 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.232 -1.158 . . . . 0.0 110.281 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.439 HD12 ' HA ' ' A' ' 3' ' ' PHE . 79.3 mt -83.16 -30.28 8.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.222 -0.923 . . . . 0.0 110.407 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.475 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -63.44 -52.52 59.67 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.281 -0.887 . . . . 0.0 110.36 -179.908 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.49 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 32.8 Cg_exo -52.81 -31.4 51.45 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 O-C-N 123.347 1.183 . . . . 0.0 110.339 179.614 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.504 HD23 ' O ' ' A' ' 9' ' ' LEU . 2.0 tt -76.96 -27.18 54.7 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.425 -0.797 . . . . 0.0 109.92 179.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -65.54 -41.54 92.93 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.428 -0.795 . . . . 0.0 109.969 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 33.2 mt -75.03 -28.91 60.64 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.545 -0.722 . . . . 0.0 110.051 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.54 -32.03 74.47 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -66.34 -26.05 67.1 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.296 -1.12 . . . . 0.0 110.001 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.467 ' O ' HG23 ' A' ' 18' ' ' ILE . 63.2 tp -80.37 -45.93 16.92 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.411 -0.806 . . . . 0.0 110.276 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.411 ' HA ' HG12 ' A' ' 18' ' ' ILE . 3.8 mmpt? -68.55 -26.53 65.46 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.345 -0.847 . . . . 0.0 110.002 -179.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 3.3 m-20 -81.38 -26.64 35.33 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.295 -0.878 . . . . 0.0 109.656 179.661 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 8.3 tt -77.23 -27.2 53.26 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.476 -0.765 . . . . 0.0 110.243 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.467 HG23 ' O ' ' A' ' 14' ' ' LEU . 14.2 pt -79.76 -21.9 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.322 -0.861 . . . . 0.0 110.331 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.407 ' N ' HG13 ' A' ' 18' ' ' ILE . 2.6 mttt -169.95 72.61 0.07 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.243 -0.911 . . . . 0.0 110.245 179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.34 0 O-C-N 119.855 -1.778 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.688 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.618 ' O ' HG22 ' A' ' 2' ' ' ILE . 47.9 mt -112.15 20.59 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.317 -0.865 . . . . 0.0 110.097 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . 0.405 ' HA ' HD12 ' A' ' 6' ' ' ILE . 46.7 t80 -64.85 -36.41 84.26 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.238 -0.914 . . . . 0.0 109.995 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.487 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -61.98 -18.11 56.55 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 179.857 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.461 ' HB3' HG22 ' A' ' 2' ' ' ILE . . . -90.16 -21.36 22.25 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.307 -1.114 . . . . 0.0 110.278 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . 0.405 HD12 ' HA ' ' A' ' 3' ' ' PHE . 82.0 mt -83.34 -29.6 7.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.31 -0.868 . . . . 0.0 110.437 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.473 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -64.39 -52.37 53.98 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.204 -0.935 . . . . 0.0 110.293 -179.916 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.487 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 31.7 Cg_exo -52.48 -31.84 50.27 Favored 'Trans proline' 0 C--N 1.313 -1.316 0 O-C-N 123.485 1.255 . . . . 0.0 110.093 179.556 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.427 HD23 ' O ' ' A' ' 9' ' ' LEU . 0.9 OUTLIER -78.92 -23.73 44.51 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.425 -0.797 . . . . 0.0 110.044 179.679 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -71.15 -29.67 65.5 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.316 -0.865 . . . . 0.0 110.225 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 79.1 mt -82.09 -27.79 32.68 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.322 -0.861 . . . . 0.0 110.274 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -77.97 -34.57 37.65 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.584 ' O ' HD23 ' A' ' 17' ' ' LEU . . . -64.17 -25.55 68.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.408 -1.054 . . . . 0.0 110.134 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 62.9 tp -85.33 -46.54 10.88 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.345 -0.847 . . . . 0.0 110.035 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.695 ' HE2' HD11 ' A' ' 18' ' ' ILE . 4.2 mmpt? -64.31 -21.39 66.59 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.526 -0.734 . . . . 0.0 110.051 -179.813 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -76.58 -36.92 57.27 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.322 -0.861 . . . . 0.0 110.185 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.584 HD23 ' O ' ' A' ' 13' ' ' ALA . 4.2 mm? -73.43 -34.4 65.42 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.356 -0.84 . . . . 0.0 110.124 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.695 HD11 ' HE2' ' A' ' 15' ' ' LYS . 1.7 pp -90.93 -22.43 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.514 -0.741 . . . . 0.0 110.399 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.1 tmtt? -137.62 97.63 3.49 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.208 -0.933 . . . . 0.0 110.152 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.282 0 O-C-N 119.798 -1.814 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ACE . . . . . . . . . . . . . . . . . . . . 0 C--O 1.214 -0.769 . . . . . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.8 pt -121.62 24.9 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.336 -0.853 . . . . 0.0 110.271 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -69.64 -45.33 68.72 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.242 -0.911 . . . . 0.0 109.872 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.482 ' O ' ' CD ' ' A' ' 8' ' ' PRO . . . -67.83 -9.05 55.4 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 179.264 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -91.23 -27.69 18.29 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.294 -1.121 . . . . 0.0 110.232 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 46.5 mm -82.62 -31.39 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.263 -0.898 . . . . 0.0 110.408 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' TRP . . . . . 0.464 ' CB ' ' HD3' ' A' ' 8' ' ' PRO . 0.0 OUTLIER -61.33 -52.46 70.53 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 121.303 -0.873 . . . . 0.0 110.612 -179.699 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.482 ' CD ' ' O ' ' A' ' 4' ' ' GLY . 31.3 Cg_exo -52.39 -33.59 57.18 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 O-C-N 123.352 1.185 . . . . 0.0 110.288 179.501 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.0 tt -77.5 -20.41 54.32 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.556 -0.715 . . . . 0.0 110.214 179.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -70.67 -31.04 67.81 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.363 -0.836 . . . . 0.0 110.264 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 7.4 mt -82.34 -26.3 33.08 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.359 -0.838 . . . . 0.0 110.201 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -82.81 -32.18 27.57 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -61.56 -31.7 71.74 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.26 -1.141 . . . . 0.0 110.245 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 63.1 tp -77.28 -48.14 18.24 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.332 -0.855 . . . . 0.0 110.123 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.465 ' HA ' HG12 ' A' ' 18' ' ' ILE . 0.0 OUTLIER -56.79 -34.03 67.25 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.404 -0.81 . . . . 0.0 110.325 179.962 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -71.78 -34.35 69.36 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.417 -0.802 . . . . 0.0 109.998 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 3.7 tp -70.01 -29.91 67.08 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.412 -0.805 . . . . 0.0 110.214 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.465 HG12 ' HA ' ' A' ' 15' ' ' LYS . 22.4 pt -90.82 -22.01 6.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.346 -0.846 . . . . 0.0 110.397 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 9.4 mmtm -82.66 -172.69 4.21 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.287 -0.883 . . . . 0.0 110.248 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.346 0 O-C-N 119.886 -1.759 . . . . 0.0 . . . . . . . . . . 0 0 . 1 stop_ save_